Colvard D S, Jankus W R, Berg N J, Graham M L, Jiang N S, Ingle J N, Spelsberg T C
Department of Biochemistry and Molecular Biology, Mayo Graduate School of Medicine, Mayo Clinic, Rochester, MN 55905.
Clin Chem. 1988 Feb;34(2):363-9.
A micro version of a nuclear binding assay to assess the biological activity of receptors for steroid hormones was developed for application to small (needle) biopsies of human tumors for the purpose of predicting responses to steroid therapy. This easier assay requires 10-fold less tissue than the original nuclear binding assay described for progesterone receptors in the avian oviduct, endometrium, and endometrial carcinomas (Spelsberg TC, et al., Endocrinology 1987;121:631). We describe the application of this micro assay to normal avian oviduct and cancers of the human breast, and we demonstrate a tissue specificity and saturation of nuclear binding. The micro assay reliably measured as little as 0.5 mg equivalents of tissue per assay tube. Results for breast tumors determined to be estrogen-receptor-positive by the standard dextran-coated charcoal method were also determined with this nuclear binding assay. As described previously for progesterone receptors in endometrial carcinomas, some receptor-positive breast biopsies displayed negligible capacity for nuclear binding. Therefore, with the present assay we have identified nonfunctional receptors in these biopsies, which may be useful for accurate prediction of patients' responses to therapy with hormones.
为了预测类固醇激素疗法的疗效,我们开发了一种用于评估类固醇激素受体生物活性的微量核结合测定法,用于对人类肿瘤的小(针吸)活检样本进行检测。这种更简便的测定法所需组织量比最初用于检测禽类输卵管、子宫内膜及子宫内膜癌中孕酮受体的核结合测定法少10倍(斯佩尔斯伯格TC等人,《内分泌学》1987年;121:631)。我们描述了这种微量测定法在正常禽类输卵管和人类乳腺癌中的应用,并证明了核结合的组织特异性和饱和度。该微量测定法每测定管能可靠检测低至0.5毫克当量的组织。用标准葡聚糖包被活性炭法测定为雌激素受体阳性的乳腺肿瘤结果,也通过这种核结合测定法得出。正如之前对子宫内膜癌中孕酮受体的描述,一些受体阳性的乳腺活检样本显示出可忽略不计的核结合能力。因此,通过目前的测定法,我们在这些活检样本中识别出了无功能的受体,这可能有助于准确预测患者对激素疗法的反应。